- Home
- OKYO vs QNCX Comparison
OKYO vs QNCX Comparison
Compare OKYO & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- QNCX
- Stock Information
- Founded
- OKYO 2007
- QNCX 2012
- Country
- OKYO United Kingdom
- QNCX United States
- Employees
- OKYO N/A
- QNCX N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OKYO Health Care
- QNCX Health Care
- Exchange
- OKYO Nasdaq
- QNCX Nasdaq
- Market Cap
- OKYO 37.0M
- QNCX 44.0M
- IPO Year
- OKYO 2022
- QNCX 2019
- Fundamental
- Price
- OKYO $1.50
- QNCX $1.03
- Analyst Decision
- OKYO Strong Buy
- QNCX Strong Buy
- Analyst Count
- OKYO 1
- QNCX 5
- Target Price
- OKYO $7.00
- QNCX $8.00
- AVG Volume (30 Days)
- OKYO 58.3K
- QNCX 128.6K
- Earning Date
- OKYO 05-06-2025
- QNCX 05-12-2025
- Dividend Yield
- OKYO N/A
- QNCX N/A
- EPS Growth
- OKYO N/A
- QNCX N/A
- EPS
- OKYO N/A
- QNCX N/A
- Revenue
- OKYO N/A
- QNCX N/A
- Revenue This Year
- OKYO N/A
- QNCX N/A
- Revenue Next Year
- OKYO N/A
- QNCX N/A
- P/E Ratio
- OKYO N/A
- QNCX N/A
- Revenue Growth
- OKYO N/A
- QNCX N/A
- 52 Week Low
- OKYO $0.81
- QNCX $0.51
- 52 Week High
- OKYO $1.74
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- OKYO 65.97
- QNCX 32.65
- Support Level
- OKYO $1.03
- QNCX $0.98
- Resistance Level
- OKYO $1.24
- QNCX $1.10
- Average True Range (ATR)
- OKYO 0.11
- QNCX 0.10
- MACD
- OKYO 0.03
- QNCX -0.00
- Stochastic Oscillator
- OKYO 70.12
- QNCX 22.94
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.